Galina Feodorovna Leskova, V I Shvets and Yu M Krasnopolskii
Institute of General Pathology und Pathophysiology, Russia Russian Technological University M V Lomonosov Institute of Fine Chemical Technologies, Russia National Technical University Kharkiv Polytechnic Institute, Ukraine
Posters & Accepted Abstracts: Int J Drug Dev & Res
Massive blood loss accompanied by hemorrhagic shock is the leading cause of the high (15-30%) mortality of victims. There is currently no significant trend towards its decline. This is because the resuscitation measures currently available are mainly aimed at protecting the normal cells that remain undamaged by the shock effect. Moreover, the onset of resuscitation is accompanied by an increase in cellular damage. The damaged cells eventually become necrotic, resulting in the patient either dying or remaining disabled. The problem of restoring the functions of damaged cells still remains unresolved due to the lack of effective methods for correcting the cellular membrane structures. L i po san (“empty” phosphatidylcholine liposomes) is a drug whose action is aimed at restoring the structure and functions of damaged cells both in the early and late stages of hemorrhagic shock. The drug is an effective agent that acts at the subcellular, organ and systemic levels. L i posan restores the structures of the liver, brain, lung and spleen to a considerable extent. When administered during late-stage experimental hemorrhagic shock, Liposan induces an increase in systemic arterial blood pressure within 20-30 minutes on average to 70 mm Hg. This is followed by a stabilization of arterial blood pressure at the subnormal level during 4 hours of observation. Animals under such conditions have their life expectancy increased by an average of 7 hours. T h e ad vantage of liposan is its high efficiency in treating latestage hemorrhagic shock in cases where conventional treatment methods, including transfusion and infusion therapy, often prove ineffective. The dispensing of liposan at the local clinic will greatly help reduce mortality and disability resulting from massive blood loss and hemorrhagic shock due to its pronounced membranerestorative action.
Galina Feodorovna Leskova completed his PhD in Pathophysiology by Institute of General Pathology. She has worked as leading researcher in laboratory of nanopathology and biomedical nanotechnologies of Institute of General Pathology und Pathophysiology. She has published more than 52 papers in reputed journals.
E-mail: lg478624@gmail.com
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 
